Funding for this research was provided by:
La Caixa Foundation (LCF/PR/GN17/10300004)
Alzheimer's Association (TriBEKa-17-519007, 2019-AARF-644568)
Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government (2017-SGR-892)
Ministerio de Ciencia, Innovación y Universidades (RYC-2013-13054, RYC2018-026053-I, FJC2018-038085-I, FJCI-2017-33437, IJC2018-037478-I)
Instituto de Salud Carlos III (CP II 17/00029, PI19/00155)
H2020 Marie Skłodowska-Curie Actions (752310)
swedish research council (2018-02532)
H2020 European Research Council (681712)
Alzheimer's Drug Discovery Foundation (201809-2016862, RDAPB-201809-2016615)
Swedish Alzheimer Foundation (AF-742881)
Received: 19 October 2020
Accepted: 20 June 2021
First Online: 27 July 2021
: The ALFA+ study (ALFA-FPM-0311) was approved by the Independent Ethics Committee “Parc de Salut Mar”, Barcelona, and registered at ExternalRef removed (Identifier: NCT02485730). All participating subjects signed the study’s informed consent form that had also been approved by the Independent Ethics Committee “Parc de Salut Mar”, Barcelona.
: MS is a full-time employee of the Roche Diagnostics International Ltd. GK is a full-time employee of the Roche Diagnostics GmbH. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, and CogRx; has given lectures in symposia sponsored by Fujirebio, Alzecure, and Biogen; and is a co-founder of the Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers and is a co-founder of the Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. MSC has served as a consultant and at advisory boards for the Roche Diagnostics International Ltd. and has given lectures in symposia sponsored by the Roche Diagnostics, S.L.U, and Roche Farma, S.A. JLM is currently a full-time employee of H. Lundbeck A/S and priory has served as a consultant or at advisory boards for the following for-profit companies, or has given lectures in symposia sponsored by the following for-profit companies: Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare, and ProMIS Neurosciences. The other authors declare that they have no competing interests.